A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

被引：3

作者：

Ott, P. A. ^{[1
,2
]}

Pavlick, A. C. ^{[3
]}

Johnson, D. B. ^{[4
]}

Hart, L. L. ^{[5
]}

Infante, J. R. ^{[6
]}

Luke, J. J. ^{[7
]}

Lutzky, J. ^{[8
]}

Rothschild, N. ^{[9
]}

Spitler, L. ^{[10
]}

Cowey, C. L. ^{[11
]}

Alizadeh, A. ^{[12
]}

Salama, A. ^{[13
]}

He, Y. ^{[14
]}

Bagley, R. G. ^{[15
]}

Zhang, J. ^{[15
]}

Hamid, O. ^{[16
]}

机构：

[1] Dana Farber Canc Inst, Melanoma Ctr, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02115 USA

[3] NYU, Sch Med, Dept Med, New York, NY USA

[4] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA

[5] Florida Canc Specialists, Hematol Oncol, Ft Myers, FL USA

[6] Tennessee Oncol PLLC, Dept Med, Nashville, TN USA

[7] Univ Chicago, Hematol Oncol, Chicago, IL 60637 USA

[8] Mt Sinai Comprehens Canc Ctr, Div Hematol Oncol, Dept Med, Miami Beach, FL USA

[9] Florida Canc Specialists, Dept Med, W Palm Beach, FL USA

[10] St Marys Hosp, Northern Calif Melanoma Ctr, San Francisco, CA USA

[11] Baylor Univ, Med Ctr, Baylor Skin Malignancy & Treatment Ctr, Dallas, TX USA

[12] Georgia Canc Specialists, Cent Res, Decatur, GA USA

[13] Duke Univ, Dept Med, Durham, NC USA

[14] Celldex Therapeut Inc, Biostat, Hampton, NJ USA

[15] Celldex Therapeut Inc, Clin Sci, Hampton, NJ USA

[16] Angeles Clin & Res Inst, Dept Translat Res ImmunoOncol, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw379.42

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1147P

引用

页数：1

共 50 条

[41] Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC).
Verheijden, Gijs
Beusker, Patrick
Ubink, Ruud
van der Lee, Miranda
Groothuis, Patrick
Goedings, Peter J.
Egging, David
Mattaar, Ellen
Timmers, Macro
Dokter, Wim
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[42] 2 for 1: Targeting tumor-associated macrophages and cancer cells with a novel MERTK-targeting antibody-drug conjugate (ADC)
Takeda, Shugaku
Lo, PuiChi
Schefer, Daniel
Siddiqui, Maryam
Tyagi, Anudishi
Battula, Venkata Lokesh
Maiti, Abhishek
Tavazoie, Sohail
Tavazoie, Masoud
Darst, David Martin
Kurth, Isabel
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[43] Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors
Sharkey, Robert M.
Ocean, Allyson J.
Starodub, Alexander N.
Bardia, Aditya
Guarino, Michael
Messersmith, Wells A.
Berlin, Jordan D.
Picozzi, Vincent J.
Moroose, Rebecca
Wegener, William A.
Maliakal, Pius
Govindan, Serengulam V.
Goldenberg, David M.
CANCER RESEARCH, 2017, 77
[44] POPULATION PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN, AN ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH CD30-POSITIVE HEMATOLOGIC MALIGNANCIES.
Li, H.
Han, T. H.
Hunder, N.
Jang, G.
Zhao, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S41 - S42
[45] Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors
Tang, Mei
Garg, Amit
Bonate, Peter L.
Rosenberg, Jonathan E.
Matsangou, Maria
Kadokura, Takeshi
Yamada, Akihiro
Choules, Mary
Pavese, Janet
Nagata, Masanori
Tenmizu, Daisuke
Koibuchi, Akira
Heo, Nakyo
Wang, Lu
Wojtkowski, Tomasz
Hanley, William D.
Poondru, Srinivasu
CLINICAL PHARMACOKINETICS, 2024, 63 (04) : 423 - 438
[46] A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors
Tolcher, A. W.
Calvo, E.
Maitland, M. L.
Gibson, B.
Xuan, D.
Joh, T.
Jackson-Fischer, A.
Damelin, M.
Barton, J.
Xin, X.
Sachdev, J. C.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S724 - S724
[47] Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer
Petrylak, Daniel P.
Kantoff, Philip
Vogelzang, Nicholas J.
Mega, Anthony
Fleming, Mark T.
Stephenson, Joe J., Jr.
Frank, Richard
Shore, Neal D.
Dreicer, Robert
McClay, Edward F.
Berry, William R.
Agarwal, Manish
DiPippo, Vincent A.
Rotshteyn, Yakov
Stambler, Nancy
Olson, William C.
Morris, Stephen A.
Israel, Robert J.
PROSTATE, 2019, 79 (06): : 604 - 613
[48] First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.
Demetri, George D.
Luke, Jason J.
Hollebecque, Antoine
Powderly, John D.
Spira, Alexander I.
Subbiah, Vivek
Lai, Dominic W.
Yue, Huibin
Kasichayanula, Sreeneeranj
Gulbranson, Scott
Purcell, James
Myzak, Melinda
Robinson, Randy
Villalobos, Victor Manuel
Tolcher, Anthony W.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[49] Phase I study of A166, an antibody-drug conjugate in advanced HER2-expressing solid tumours
Zhang, Jian
Liu, Rujiao
Gao, Shuiping
Li, Wenhua
Chen, Yang
Meng, Yanchun
Liu, Chang
Jin, Wenyue
Wu, Junyan
Wang, Ying
Hao, Yanrong
Yi, Shuli
Qing, Yan
Ge, Junyou
Hu, Xichun
NPJ BREAST CANCER, 2023, 9 (01)
[50] A novel pegylated biparatopic antibody-drug conjugate (pb-adc) targeting cancers with low HER2+ expression
Liu, Shumin
Yin, Shuqiang
Lyu, Weidong
Lei, Yang
Zhuo, Qiudong
Wu, Zibin
Tan, Shuangyu
Zheng, Liling
Wen, Yu
Wu, David
CANCER RESEARCH, 2022, 82 (12)

← 1 2 3 4 5 →